0001293971-20-000009.txt : 20200312 0001293971-20-000009.hdr.sgml : 20200312 20200312161151 ACCESSION NUMBER: 0001293971-20-000009 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200306 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200312 DATE AS OF CHANGE: 20200312 FILER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 20708898 BUSINESS ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 8-K 1 blue-20200306.htm 8-K blue-20200306
0001293971FALSE00012939712020-03-062020-03-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________
FORM 8-K
__________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 6, 2020
__________________________
bluebird bio, Inc.
(Exact name of Registrant as Specified in Its Charter)
_____________________________________________________________
Delaware
001-35966
13-3680878
(State or Other Jurisdiction
of Incorporation)		(Commission File Number)(IRS Employer
Identification No.)
60 Binney Street,
Cambridge, MA
02142
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (339) 499-9300
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value per shareBLUEThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 1.01 Entry into a Material Definitive Agreement.

On March 6, 2020, bluebird bio (Switzerland) GmbH, a wholly-owned subsidiary of bluebird bio, Inc. (“bluebird”) and Apceth Biopharma GmbH entered into an amendment (the “Amendment”) to the Toll Manufacturing and Service Agreement, effective January 1, 2017, for the manufacture of the drug product (the “Agreement”) to modify the terms applicable to reserved production capacity.

The foregoing description of the terms of the Amendment does not purport to be complete, and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.


Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
Exhibit
No.		Description
10.1†
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
†
Certain portions of the exhibit (indicated by asterisks) have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause competitive harm to bluebird if publicly disclosed.





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 12, 2020bluebird bio, Inc.
By:/s/ Jason F. Cole
Jason F. Cole
Chief Operating and Legal Officer


 EX-10.1 2 exhibit10120200306.htm EX-10.1 Document
Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.


Exhibit 10.1
Amendment Agreement No. 3
to the
Toll Manufacturing and Service Agreement

Amendment Agreement No. 3 ("Amendment No. 3") to the Toll Manufacturing and Service Agreement (i.e. the TMSA as further defined below) shall become effective from the date on which it was signed by the last Party and is entered into by and between:
bluebird bio (Switzerland) GmbH ("BBB")
having its principal place of business at Dammstraße 21, 6300 Zug, Switzerland,

and

Apceth Biopharma GmbH ("APCETH")
having its principal place of business at Haidgraben 5, 85521 Ottobrunn, Germany

BBB and APCETH hereinafter also each referred to as a "Party" and jointly as the "Parties".

Furthermore,

bluebird bio Inc.
having its principal place of business at 60 Binney St., Cambridge, MA 02142, United States of America,

acknowledges this Amendment No. 3 as guarantor for BBB's obligations under the TMSA.

Whereas,
bluebird bio, Inc., APCETH and KG entered into a Toll Manufacturing and Service Agreement effective on January 1, 2017 regarding the clinical and commercial GMP-manufacturing of bluebird bio, Inc.’s Products and related services by APCETH, including an Addendum of May 21, 2018 regarding the European Union’s General Data Protection Regulation and an Amendment No. 1 of November 16, 2018 regarding indemnification of APCETH (collectively the "TMSA"). By letter of May 15, 2019, received by APCETH at May 22, 2019, bluebird bio, Inc. formally assigned and transferred the TMSA to its subsidiary BBB (the "Assignment") in accordance with the provisions of Section 23.1 of the TMSA effective April 28, 2019 as further reflected in Amendment Agreement No. 2 to the TMSA effective September 5, 2019.
The Parties now wish to make further amendments to the TMSA as detailed herein in this Amendment No. 3.
NOW THEREFORE, the Parties agree as follow:
1. Amendments to the TMSA
1.1 Section 1.12 of the TMSA shall be replaced by the following revised Section 1.12:
1.12 “Clean Room” shall mean [***].
1.2. Section 1.34 of the TMSA shall be replaced by the following revised Section 1.34:
1.34 “Product” shall mean the autologous cells transduced with a defined lentiviral vector suspended in cryopreservative solution in the final immediate container for [***].
apceth ./. BBB
Amendment No. 3 to the TMSA
Page 1
Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.


1.3 In Section 3.2 of the TMSA, new subsections (c) and (d) shall be added as follows:
(c) Availability of a [***]. At any time after the effective date of Amendment No. 3 to this Agreement, BBB shall [***].
(d) Additional [***]. If the Parties come to the conclusion [***].
1.4 Section 4.2 of the TMSA, including its subsections (a) through (f), shall be replaced by the following revised Section 4.2; the new Schedule 4 introduced thereby is attached hereto as Annex 3:
4.2 Capacity, Production Scenarios, Forecasts, Additional Batch and Cancellation Fee. The reserved production capacity of the Clean Rooms and the minimum and maximum amount of Batches to be ordered by BBB and to be delivered by APCETH for each [***] is determined by the Production Scenarios set forth in ascending order in Section 1 of Schedule 4 elected by BBB (each a “Production Scenario”) and as further provided and subject to Schedule 4.
1.5 Behind current Section 4.3 of the TMSA a new Section 4.4 shall be added:
4.4 Multi-Batch Processing / Staggered Start. For the avoidance of doubt, each Batch as defined in Section 1.7 of this TMSA is a quantity of a Product [***].
1.6 Behind new Section 4.4 of the TMSA a new Section 4.5 shall be added:
4.5 Product Overlaps. BBB acknowledges that currently APCETH may only manufacture one kind of Product [***].
1.7 Section 5.3 of the TMSA shall be deleted.
1.8 Behind new Section 5.5 of the TMSA the following new Section 5.6 shall be added to the TMSA:
5.6 Undelivered Product. APCETH shall inform BBB in writing [***].
1.9 In Section 6.1 of the TMSA, the following sentence shall be added to the existing provision after the first sentence and before the current second and third (then third and fourth) sentences; 'Schedule 5' referred to in such new sentence is attached to this Amendment No. 3 as Annex 1.9:
BBB shall target to maintain and timely provide to APCETH sufficient stock level—either in on-site or third-party storage—of Supplied Materials as necessary to enable APCETH to manufacture the amount of Batches forecasted for approximately [***] under the then current Forecast; as defined in more detail in Schedule 5 (“Critical BBB Supplied Raw Material”). If supply of BBB sourced material becomes a constraint, BBB will communicate and work with APCETH to manage supplies in an appropriate manner.
1.10 Behind the current Section 6.3 of the TMSA, new Sections 6.4, and 6.5 to the TMSA shall be added; 'Schedule 6' referred to in such new Section 6.4 is attached to this Amendment No. 3 as Annex 1.9:
6.4 Apceth shall target to maintain a sufficient stock level of material essential for the manufacture of the Product other than the Supplied Material as necessary to manufacture the amount of Batches forecasted under the then current Forecast for the following [***]; as defined in more detail in Schedule 6 (“Critical Apceth Supplied Raw Material” ). On hand BBB-supplied critical raw materials and hand inventory of Drug Product will be reported to BBB [***]. If supply of APCETH-sourced material becomes a constraint,
apceth ./. BBB
Amendment No. 3 to the TMSA
Page 2
Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.


APCETH will communicate and work with BBB to manage supplies in an appropriate manner.
6.5 Apceth, acting in its own name and on behalf of BBB as an indirect representative of BBB for customs purposes, will make all customs declarations to the competent authorities for the import (release for fee circulation in the EU) of the Supplied Material by BBB under this Agreement. Therefore, BBB ensures that it will to best of its knowledge provide Apceth all necessary, correct and complete information, including the declared value, required for the import of the Supplied Materials.

1.11 In Section 11.1 of the TMSA, a new subsection (c) shall be added as follows:
(c) [***]: One million (1,000,000) EUR.
1.12 Section 11.2 of the TMSA shall be replaced by the following revised Section 11.2:
11.2 Maintenance Fee. Effective following the Supply Initiation Date, BBB shall pay to APCETH a maintenance fee to [***]. The Maintenance Fee for the [***]. Effective following the Extension Date, the [***] to be paid by BBB to APCETH shall amount to [***]; provided, however, that
(i) the applicable Maintenance Fee for the calendar year [***]; and
(ii) prior to BBB’s exclusive access to [***].
1.13 Section 11.3 of the TMSA shall be replaced by the following revised Section 11.3:
11.3 Production Fees.
(a) The Production Fee for each Production Year shall represent the [***]. For any Additional Batch, to the extent that a Production Scenario allows for Additional Batches, the price per Additional Batch set forth in Section 3 of Schedule 4 ("Additional Batch Price") shall apply.
(b) The respective (minimum) Production Fee shall be due and payable in [***], where the Production Fee applicable to [***]. Any Additional Batch Prices will be invoiced [***].
1.14 Section 11.8 of the TMSA shall be replaced by the following revised Section 11.8:
11.8 Invoice. APCETH will invoice BBB [***].

1.15 Section 16.2 of the TMSA, as last changed by Amendment No. 1 thereto, shall be replaced with the following Section 16.2:
16.2 Indemnification of APCETH. BBB will indemnify APCETH, its Affiliates, its approved subcontractors and its and their respective directors, officers, employees, independent contractors, consultants and agents (the “APCETH Parties”), and defend and hold each of them harmless, from and against any and all Losses to the extent such Losses arise out of or result from any claim, lawsuit or other action or threat by a Third Party arising out of: [***].
1.16 Schedule 1 of the TMSA shall be replaced by the updated Schedule 1 attached hereto.
apceth ./. BBB
Amendment No. 3 to the TMSA
Page 3
Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.


1.17 Schedule 2 shall be replaced by the updated Schedule 2 attached hereto.
1.18 Schedule 3 shall be replaced by the updated Schedule 3 attached hereto.
1.19 Except as expressly provided in Sections 1.1 through 1.18 of this Amendment No. 3, all other terms, conditions and provisions of the TMSA shall continue in full force and effect as provided therein.
2. Severability
If any provision of this Amendment No. 3 is or becomes invalid, either as a whole or in part, this shall not affect the validity or enforceability of the remainder of this Amendment No. 3 or the Agreement. The Parties agree to replace the invalid provision by a provision which serves the purposes of this Amendment No. 3 and the Agreement as closely as possible. The same shall apply to any possible omission in this Amendment No. 3. If the defectiveness of a provision is based on the determination of a certain level of performance or a certain time (deadline or fixed date), the provision is deemed to have been agreed with the level or time which comes as close as legally possible to the original level or time.

(Signature page follows)
apceth ./. BBB
Amendment No. 3 to the TMSA
Page 4
Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.


IN WITNESS WHEREOF, the Parties have caused this Amendment No. 3 to be executed and delivered by their respective duly authorized officers

bluebird bio (Switzerland) GmbH   apceth Biopharma GmbH
Zug, 06-Mar-2020    Ottobrunn 05.03.2020
(Place, Date)    (Place, Date)


/s/ David Seeberger    /s/ Dusan Kosijer
Name: David Seeberger   Name: Dusan Kosijer
Title: Head of Finance, Europe   Title: CFO


Acknowledged as guarantor according
to Section 23.1 TMSA:
bluebird bio, Inc.
Cambridge, MA 06-Mar 2020
(Place, Date)


/s/ Jason Cole
Name: Jason Cole
Title: Chief Operating and Legal Officer



apceth ./. BBB
Amendment No. 3 to the TMSA
Page 5
Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.


[***]
apceth ./. BBB
Amendment No. 3 to the TMSA
Page 6
 EX-101.SCH 3 blue-20200306.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 blue-20200306_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 blue-20200306_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 blue-20200306_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name City Area Code City Area Code Cover page. Cover page. Document Type Document Type Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 blue-20200306_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover
Mar. 06, 2020
Cover page.  
Document Period End Date Mar. 06, 2020
Entity Registrant Name bluebird bio, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-35966
Entity Tax Identification Number 13-3680878
Entity Address, Address Line One 60 Binney Street
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 339
Local Phone Number 499-9300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol BLUE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001293971
Amendment Flag false
Document Type 8-K
XML 13 blue-20200306_htm.xml IDEA: XBRL DOCUMENT 0001293971 2020-03-06 2020-03-06 0001293971 false 8-K 2020-03-06 bluebird bio, Inc. DE 001-35966 13-3680878 60 Binney Street Cambridge MA 02142 339 499-9300 false false false false Common Stock, $0.01 par value per share BLUE NASDAQ false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "blue-20200306.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "blue-20200306_cal.xml" ] }, "definitionLink": { "local": [ "blue-20200306_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "blue-20200306.htm" ] }, "labelLink": { "local": [ "blue-20200306_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "blue-20200306_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "blue-20200306.xsd" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "blue", "nsuri": "http://www.bluebirdbio.com/20200306", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20200306.htm", "contextRef": "id1b93668295745f986e909766cc48a0e_D20200306-20200306", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.bluebirdbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20200306.htm", "contextRef": "id1b93668295745f986e909766cc48a0e_D20200306-20200306", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page.", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001293971-20-000009-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001293971-20-000009-xbrl.zip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end XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.bluebirdbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports blue-20200306.htm blue-20200306.xsd blue-20200306_cal.xml blue-20200306_def.xml blue-20200306_lab.xml blue-20200306_pre.xml exhibit10120200306.htm http://xbrl.sec.gov/dei/2019-01-31 true true